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Abstract
Background: To investigate the changes of the neoplastic microenvironment during the different
morphological alterations of hyperplastic and pre-invasive breast lesions.
Methods:  78 in situ ductal carcinomas of all degrees of differentiation, 22 atypical ductal
hyperplasias, 25 in situ lobular carcinomas, 18 atypical lobular hyperplasias, 32 ductal epithelial
hyperplasias of usual type and 8 flat atypias were immunohistochemically investigated for the
expression of vascular endothelial growth factor (VEGF), smooth muscle actin (SMA) and CD34,
while microvessel density (MVD) was counted using the anti-CD31 antibody.
Results: VEGF expression was strongly correlated with MVD in all hyperplastic and pre-invasive
breast lesions (p < 0.05). Stromagenesis, as characterized by an increase in SMA and a decrease in
CD34 positive myofibroblasts was observed mostly around ducts harboring high grade in situ
carcinoma and to a lesser extent around moderately differentiated DCIS. In these two groups of
in situ carcinomas, a positive correlation between MVD and SMA (p < 0.05) was observed. On the
contrary, CD34 was found to be inversely related to MVD (p < 0.05). No statistically significant
changes of the stromal fibroblasts were observed in low grade DCIS neither in any of the other
lesions under investigation as compared to normal mammary intra- and interlobular stroma.
Conclusion: Angiogenesis is observed before any significant fibroblastic stromagenesis in pre-
invasive breast lesions. A composite phenotype characterized by VEGF positive epithelial cells and
SMA positive/CD34 negative stromal cells, is identified mostly in intermediate and high grade DCIS.
These findings might imply for new therapeutic strategies using both anti-angiogenic factors and
factors selectively targeting tumor stroma in order to prevent the progression of DCIS to invasive
carcinoma.
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Background
There is considerable body of evidence from many inves-
tigations, that the stroma immediately adjacent to a
tumor is not a passive structural element that elicits an
immune response in an attempt to reject the tumor, but
an element that actively participates and contributes to
tumor progression [1-5]. Furthermore, it has been pro-
posed that carcinogenesis does not result from epithelial
or stromal mutations alone, but rather from the loss or
breakdown of biological structures induced by perturbed
stromal-epithelial interactions [6,7]. Recent data have
demonstrated that the tumor microenvironment facili-
tates metastatic spread by eliciting reversible changes in
the phenotype of cancer cells [8]. A key cell type involved
in the development of the tumor-promoting reactive
stroma appears to be the myofibroblast [9,10].
It has been shown that carcinoma cells have the capacity
to induce normal fibroblasts to turn into the reactive
myofibroblastic phenotype. Substances which are synthe-
sized by these myofibroblasts such as collagen I and II,
fibronectin isoforms, tenascin and versican as well as pro-
teases that are expressed by myofibroblasts such as metal-
loproteinases (MMPs), urokinase plasminogen activator
and fibroblast activating factor (FAP) induce a remodeling
of the extracellular matrix (ECM) that could stimulate
cancer growth and migration. Moreover, myofibroblasts
secrete growth factors, such as the connecting tissue
growth factor (CTGF) and the transforming growth factor
beta-1 (TGF beta1) which have potent angiogenic activi-
ties [11].
The mesenchymal fibroblastic stroma reactions that are
induced by, and regulated parallel to epithelial neoplastic
transformation, are termed "stromagenesis".
In the mammary gland, based on experimental studies,
Cuhiermann [12] defined three stages of stromagenesis:
"normal", "primed" and "activated". The term normal
stroma  stands for a neoplastic progression-restraining
environment, the term primed stroma for a permissive and
supportive landscape for tumor progression and the term
activated stroma for the advanced neoplastic microenviron-
ment. During breast stromagenesis there is downregula-
tion of some stromal genes, such as CD34 and
upregulation of other genes indicative of myofibroblastic
differentiation, such as smooth muscle actin (SMA) [13].
On the other hand, another key step in tumor progression
is the formation of new blood vessels from a pre-existing
vascular network, known as angiogenesis [14,15]. It has
been demonstrated that an important event in the process
of angiogenesis is the recruitment of endothelial progeni-
tor cells to sites of the new vessel formation with subse-
quent differentiation into mature endothelial cells. This
phenomenon is induced by angiogenic chemokines pro-
duced by the neoplastic cells [16]. In the mammary gland,
the formation of a vascular stroma was found to precede
invasion [17,18], while higher levels of angiogenic marker
molecules seem to be associated with poor prognosis
[19]. It has been postulated that tumor cells do not invade
into normal breast stoma but rather into a richly vascular
stroma that they have induced. This process of neovascu-
larization is driven by growth factors released into the
stroma by tumor cells and immune cells. One of these
growth factors, the vascular endothelial cell growth factor
(VEGF) was found to be overexpressed in neoplastic intra-
ductal and intralobular breast lesions as compared to nor-
mal glandular structures [20]. Yet, the results of the
relationship between VEGF expression and the degree of
vascularization in pre-invasive breast lesions are contro-
versial [20,21]. In the present study we sought to deter-
mine by immunohistochemistry, the steps of
periglandular stromal transformation in all types of pre-
invasive breast lesions in respect of their angiogenic and
stromagenic potential.
Methods
This study was approved by the Ethical Committee of
"IASO" Hospital, Athens, Greece.
Specimens
Archival material from the files of the Department of
Pathology, "IASO" Hospital was used for the study. Four
4µ thick sections were cut from the paraffin blocks of 78
in situ ductal carcinomas of all degrees of differentiation
(21 low grade/DCIS-L, 24 intermediate grade/DCIS-I and
33 high grade/DCIS-H) classified according to Holland
et.al [22], 9 atypical ductal hyperplasias/ADH, 25 in situ
lobular carcinomas/LCIS, 11 atypical lobular hyperpla-
sias/ALH, 32 ductal epithelial hyperplasias of usual type/
HUT and 8 flat atypias/FA. Consecutive sections were
used in order to obtain a better comparison between mor-
phology and protein expression. Normal mammary
parenchyma obtained from 10 women who underwent
breast reduction was also analyzed.
Immunohistochemistry
Immunohistochemical staining was performed using the
EnVision+ System-HRP. Tissue sections were deparaffin-
ized, rehydrated and treated with a hydrogen peroxide
solution for 10 min to quench endogenous peroxidase.
Sections were then heated in a microwave oven at 600 W
for 30 min in Target Retrieval Buffer, pH = 6.0 (DakoCy-
tomation). After cooling for 20 min, they were incubated
with the primary antibody (rabbit anti-human VEGF,
dilution 1:100, Oncogene Research Products, mouse anti-
human CD31, clone JC70A, dilution 1:80, Dako Corpora-
tion, mouse anti-human CD34, dilution 1:50, clone
QBEnd/10, Neomarkers and mouse anti-human a-SMA,BMC Cancer 2008, 8:88 http://www.biomedcentral.com/1471-2407/8/88
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dilution 1; 600, Dako) for 1 hour at room temperature
and then incubated for 45 min with the anti-mouse HRP
labeled polymer, included in the EnVision Kit. Finally sec-
tions were treated with a diaminobenzidine (DAB) chro-
mogenic substrate for 10 min, counterstained with
Mayer's hematoxylin, dehydrated and coverslipped.
Evaluation of microvascular density (MVD)
Images were captured using a Zeiss Axiolab microscope
(Carl Zeiss Jena GmbH, Jena, Germany) with a mechani-
cal stage, fitted with a Sony-iris CCD videocamera (Sony
Corporation, Tokyo, Japan). The video camera was con-
nected to a Pentium II personal computer loaded with the
Image Scan Software (Jandel Scientific, Erkrath, Ger-
many). In each case, 3–5 optical fields × 200 were selected
from the periphery of each gland harboring an intraepi-
thelial proliferation. Counts were done at a rim of 500 µm
in width from the periphery of each structure. In normal
breast, each duct-lobular structure was considered as one
separate entity and the whole inter- and intralobular
stroma was evaluated. Pictures were stored as JPEG files
[(1550 × 1070 pixels, 16.7 million colors (24-bit)]. Single
endothelial cells or clusters of endothelial cells, with/
without obvious lumen, positive for CD31 were consid-
ered as individual vessels. In each vessel, the outline was
interactively identified. The presence of blood cells or
fibrin without any detectable endothelial cells was not
considered sufficient to define a microvessel. Areas with a
dense leukocytic or hemorrhagic infiltration were
excluded. Vessels with muscular wall were not counted;
however, there was no restriction regarding the size of the
countable microvessels, so as not to underestimate longi-
tudinal sections or bifurcations of microvessels.
Evaluation of labeling
Positive staining of VEGF was detected in the cytoplasm of
the epithelial cells. Immunoreactivity for VEGF was evalu-
ated semiquantitatively by two independent pathologists
(K.P. and P.Y.) with reference to both the staining inten-
sity and the positively stained area. Staining intensity was
scored as follows: 0, none; 1, weak; 2, moderate; 3, strong.
The positively stained area was expressed as the percent-
age of the whole area under evaluation and scored as: 0,
none; 1: 1–25%, 2: 26–50%, 3: 51–75% and 4: 76–
100%). The product was then graded as 0–2 = low, 3–5 =
intermediate and 6–7 = high.
Fibroblastic reactivity for CD34 and a-SMA was evaluated
using the same protocol as for angiogenesis. It was
recoded as positive (+), negative (-) or intermediate (+/-)
where the staining was focal.
Statistical analysis
The mean microvascular density was calculated for each
histological group. For each study group, the positivity
index for each staining was calculated as the ratio of spec-
imens being strongly or intermediately stained over the
sample population. The positivity index of each histolog-
ical group was then correlated to the group's mean MVD,
using the Pearson r test. Both SMA and CD34 expression
pattern for every histological entity in this study were
compared with the relevant expression of the normal
breast tissue. Further analysis was performed on the DCIS
samples as these seem to differ from normal tissue. For the
comparisons between normal breast tissue samples with
the other histology groups, the Fisher exact probability
test for contingency tables larger than 2 × 2, was applied.
Every observation presented with p < 0.05 was considered
as significant.
Results
In the normal breast, all duct-lobular units exhibited
CD34 positive fibroblasts while there was no expression
of SMA myofibroblasts with the exception of four cases
showing weak focal staining. Nearly the same pattern of
fibroblastic expression was observed around glands show-
ing HUT, ADH, FA, ALH, LCIS and DCIS-L, as shown in
Table 1. A dramatic decrease of CD34 expression of
fibroblasts and acquisition of SMA was mostly observed
around ducts harboring DCIS-I and DCIS-H. Interest-
ingly, in four cases of DCIS-I and three cases of DCIS-H a
homogenous pattern of staining was observed with
fibroblasts being strongly positive to both CD34 and
SMA.
Taking into consideration the fact that, in DCIS-I and
DCIS-H, the SMA positivity index was higher, while the
CD34 positivity index was lower than the rest groups of
study (Table 2), it was necessary to define whether this dif-
ference was of significance. As shown (Table 3) there was
no statistical difference between the normal samples and
the histological groups HUT, ADH, FA, ALH, LCIS and
low grade DCIS (DCIS-L) regarding SMA and CD34 stain-
ing. On the contrary both SMA and CD34 expression pat-
terns were revealed significantly different on DCIS-I and
DCIS-H when compared to normal breast tissue samples.
Additionally, the analysis performed on the DCIS samples
alone, showed that both SMA and CD34 staining patterns
were significantly different between the three groups of
study DCIS-L, DCIS-I and DCIS-H (Table 3).
Serial sections were taken from each case and were stained
with VEGF and CD31 for the assessment of angiogenesis.
It has been shown that the highest VEGF levels were
observed in DCIS-H, while high and intermediate VEGF
values were encountered in DCIS-I and DCIS-L and to a
lesser extent in FA. All other morphological entities under
investigation presented mostly low VEGF expression. The
evaluation of angiogenesis with anti-CD31 antibody
revealed that high microvessel counts were strongly asso-BMC Cancer 2008, 8:88 http://www.biomedcentral.com/1471-2407/8/88
Page 4 of 8
(page number not for citation purposes)
ciated with DCIS-I and DCIS-H, with a mean of 140 ± 32
and 146 ± 38 respectively and to a lesser extent with DCIS-
L, ADH, FA, LCIS and ALH (mean values 121 ± 13, 119 ±
10, 114 ± 9, 111 ± 7 and 109 ± 5 respectively). Microvessel
counts around normal breast ducts and lobules and
around ducts harboring HUT were found to be signifi-
cantly lower (Table 1).
There was a strong correlation between VEGF, SMA, CD34
and microvascular density. As shown in Fig. 1, VEGF
expression was strongly correlated with MVD (p < 0.05).
A positive correlation was revealed between SMA staining
and MVD (p < 0.05) (Fig. 2). CD34 staining was proved
to be inversely related to MVD (p < 0.05) (Fig. 3).
Discussion
Over the past decade the "tissue-microenvironment" con-
cept of malignancy has gained space over the epithelio-
centric view of tumorigenesis [23,24]. The emerging
concept from several investigations implies that loss of tis-
sue architecture or derangement of cell adhesion would
drive malignant behavior of cells within a tissue, even in
the absence of primary genetic mutations. This phenome-
non could be induced by perturbed stromal-epithelial
interactions. Moreover, a repression of the malignant phe-
notype of genetically aberrant cells has been observed
after restoration of tissue organization. The Tissue Organ-
ization Field Theory proposes that proliferation is "the
default state of all cells" [25,26].
In breast carcinogenesis, several experimental studies have
focused on tumor-microenvironment interactions. Using
laser capture microdiscection, Kurose et. al. [2] identified
frequent loss of heterozygocity (LOH) in both neoplastic
epithelial and stromal compartment. The most important,
they noted that genetic alterations occurred in the epithe-
lial compartment on the earlier steps, followed by LOH in
the stromal compartments, which indicates that the
genetic alterations in the epithelia precede the ones in the
stroma. Another group of investigators also supports the
concept of stromal-epithelial interactions in the develop-
ment and progression of mammary neoplasia but in their
study the genetic alterations of the stromal cells were
found to precede genotypic changes in the epithelial cells
[27]. It seems that the switch from fibroblasts to myofi-
broblasts simulates cancer progression via an epithelial-
mesenchymal transition [28].
The results of our study are more consistent with those of
the former investigators. Stromal changes as identified
immunohistochemically by loss or dramatic increase of
CD34 positive fibroblasts and detection of SMA-reactive
myofibroblasts were observed mostly around ducts har-
boring moderately or poorly differentiated in situ carci-
noma (Fig. 4A–D). This finding might imply that stromal
changes are a late and possibly surrogate event in a proc-
ess of multistage carcinogenesis and local invasion. Yet,
recent studies on the molecular evolution of breast cancer
have raised the possibility that moderately and poorly dif-
ferentiated ductal carcinomas in situ might represent
clonal proliferations of different cytogenetic clones
[29,30]. The steps from atypical epithelial hyperplasia, to
intraductal and then to invasive carcinoma are not any
more considered as being always part of a linear progres-
sion [30]. If this is true, one could speculate that tumor
stroma, in order to be induced, needs to interact with epi-
Table 1: Presentation of the positivity indices (PI) of CD34, SMA and VEGF among the histological groups of study, in relation to MVD. 
CD34 and SMA reactivities are graded as negative (n), intermediate (i) and positive (p). VEGF expression is evaluated by the product 
of staining intensity score multiplied with the percentage of the staining area score. This product is graded as low (L), intermediate (I) 
and high (H).
STAINING CD34 (n) CD34 (i) CD34 (p) CD34 (PI) SMA (n) SMA (i) SMA (p) SMA (PI) VEGF (L) VEGF (I) VEGF (H) VEGF (PI) MVD Mean(vessel 
number/mm2) ± SD
NORMAL (n = 20) 0 0 20 1 16 4 0 0.2 18 2 0 0.1 86 ± 3
HUT (n = 32) 0 0 32 1 30 2 0 0.062 32 0 0 0 79 ± 7
ADH (n = 22) 1 1 20 0.954 21 1 0 0.045 13 3 6 0.409 119 ± 10
FA (n = 8) 0 1 7 1 7 0 1 0.125 4 2 2 0.5 114 ± 9
DCIS-L (n = 21) 0 4 17 1 14 6 1 0.333 5 12 4 0.761 121 ± 13
DCIS-I (n = 24) 8 5 11 0.667 0 11 13 1 5 14 5 0.791 140 ± 32
DCIS-H (n = 33) 25 5 3 0.242 0 0 33 1 6 11 16 0.818 146 ± 38
ALH (n = 11) 0 0 11 1 11 0 0 0 11 0 0 0 109 ± 5
LCIS (n = 25) 0 1 24 1 22 3 0 0.12 15 9 1 0.4 111 ± 7
Table 2: Comparison between normal breast tissue and the histological groups of study according to SMA and CD34 staining. It is 
shown that only DCIS-I and DCIS-H differ significantly from normal breast tissue. (The significant p values are underlined)
HUT ADH FA ALH LCIS DCIS-L DCIS-I DCIS-H
Normal (SMA) P = 0.18 P = 0.17 P = 0.21 P = 0.26 P = 0.68 P = 0.59 P < 10-9 P < 10-14
Normal (CD34) P~1.0 P~1.0 P = 0.28 P~1.0 P~1.0 P = 0.11 P < 10-4 P = 0.002BMC Cancer 2008, 8:88 http://www.biomedcentral.com/1471-2407/8/88
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thelial neoplastic cells harboring distinct genetic altera-
tions.
Low grade ductal carcinoma in situ and in situ lobular car-
cinoma are now believed to belong to the same low-grade
pathway of progression to invasive carcinoma [31]. The
cytogenetic similarities encountered in these two mor-
phologically distinct entities, namely losses in 16q and
gains in 1q chromosomes, might justify for the absence in
our study, of tumor-microenvironment alterations, for
both lesions, regarding the expression of CD34 and SMA.
Moreover, no statistical difference was found between the
normal samples and the histological groups HUT, ADH,
FA and ALH regarding SMA and CD34 staining pattern.
In our study, angiogenesis, as evaluated by the measure-
ment of MVD, was observed before any significant fibrob-
lastic stromagenesis, since a high microvessel count was
found in all in situ ductal carcinomas and to a lesser extent
around glands harboring ADH, FA, LCIS and ALH, while
stromagenesis was mostly observed around ducts harbor-
ing DCIS-I and DCIS-H. Moreover, the pattern of neovas-
cularization was characterized by a diffuse increase in
stromal vascularity between ducts (Fig. 4E). It has been
suggested that the angiogenic pathway corresponding to
the diffuse pattern is more likely to be controlled by VEGF
[32]. Indeed, in our study, there was a statistically signifi-
cant relationship between VEGF immunohistochemical
expression and the degree of MVD. Pre-invasive lobular
lesions, flat atypias and ductal hyperplasias of usual type
were weakly positive for VEGF and associated to a low
Table 3: Comparison between the DCIS groups according to 
SMA and CD34 staining. It is shown that the three groups differ 
significantly from each other both in SMA and CD34 staining.
DCIS-H DCIS-I
DCIS-L (SMA) P < 10-13 P < 10-6
DCIS-I (SMA) P < 10-4
DCIS-L (CD34) P < 10-10 P < 10-2
DCIS-I (CD34) P < 10-3
Correlation analysis between VEGF positivity index and  microvascular density (MVD) Figure 1
Correlation analysis between VEGF positivity index 
and microvascular density (MVD). A significantly posi-
tive correlation between VEGF staining and microvascular 
density, is showed (p < 0.05).
Correlation analysis between SMA positivity index and  microvascular density (MVD) Figure 2
Correlation analysis between SMA positivity index 
and microvascular density (MVD). A significantly posi-
tive correlation between SMA staining and microvascular 
density, is showed (p < 0.05).
Correlation analysis between CD34 positivity index and  microvascular density (MVD) Figure 3
Correlation analysis between CD34 positivity index 
and microvascular density (MVD). A significantly nega-
tive correlation between CD34 staining and microvascular 
density, is showed (p < 0.05).BMC Cancer 2008, 8:88 http://www.biomedcentral.com/1471-2407/8/88
Page 6 of 8
(page number not for citation purposes)
Study of SMA expression among high and low grade ductal carcinoma in situ, revealed that there are no SMA positive myofi- broblasts around DCIS-L (B) while around high grade DCIS, SMA positive myofibroblasts are identified (A) Figure 4
Study of SMA expression among high and low grade ductal carcinoma in situ, revealed that there are no SMA 
positive myofibroblasts around DCIS-L (B) while around high grade DCIS, SMA positive myofibroblasts are 
identified (A). The opposite phenomenon is observed regarding CD34 expression upon stroma fibroblasts. It is shown that 
in high grade DCIS there is a dramatic decrease of CD34 positive fibroblasts (C) as opposed to the CD34 positive stroma 
fibroblasts of DCIS-L (D). CD 31 staining showing a high microvessel density of the stroma adjacent to a DCIS-H (E). Arrow-
heads showing CD 31 positively stained vessels. Magnification × 100.BMC Cancer 2008, 8:88 http://www.biomedcentral.com/1471-2407/8/88
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degree of neovascularization while in all in situ ductal car-
cinomas VEGF was highly expressed (Fig. 5A and 5B).
In the context of the above analysis, our results support
the thesis that as the level of aggressiveness increases in
the DCIS group from low to high, CD34 seems to be grad-
ually down-regulated in the adjacent stroma while SMA
seems to be gradually up-regulated. It has been suggested
that this phenomenon might represent a change from a
multipotent mesenchymal cell to a committed cell type
[1]. Such an altered phenotype might be associated with a
more favorable environment for the carcinoma, as far as
possible infiltration and dissemination are concerned. In
the present work, this alteration in the stroma phenotype
was not evident in other hyperplastic and pre-malignant
lesions such as LCIS or breast atypias which are thought to
be less likely to progress to invasion [1].
Conclusion
Our findings suggest that angiogenesis is observed before
any significant fibroblastic stromagenesis in pre-invasive
breast lesions. A composite phenotype characterized by
VEGF positive epithelial cells and SMA positive/CD34
negative stromal cells, is identified mostly in intermediate
and high grade in situ ductal carcinomas. This observation
might imply for new therapeutic strategies to prevent the
progression of DCIS to invasive carcinoma, using both
anti-angiogenic factors and factors selectively targeting
tumor stroma.
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